MENU

CSL clinical studies prove successful

CSL (ASX: CSL) has a long and proud history of developing therapies to improve patients’ lives. This week CSL announced  promising results from “clinical studies involving a new group of therapies for the treatment of haemophilia”.

One of the beauties of CSL’s business model has been the company’s ability to innovate therapies, through research and development, which improve upon and expand upon its current sales base. CSL has for many years provided blood plasma products to treat hemophilia  so news of a potential new therapy for bleeding disorders (including hemophilia) and the associated development have low business risks given CSL already knows the market well and services it extensively.

Another firm which also has a similarly low-risk business model is implantable hearing device company Cochlear (ASX: COH). Cochlear is continually innovating improvements to its products, which effectively value adds to its current customer base.

The quality of these two firms’ business models has been reflected in their share prices, with CSL and Cochlear up 84% and 37% respectively over the past five years. In comparison the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) is down around 4% over the same period.

In the market for high-yielding ASX shares? Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!